



Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

Synthetic Biology Can Turn Pharmaceutical Manufacturing into a Programmable Design Problem

Elena Petrova^{1*}, Ivan Georgiev¹, Nikolay Stoyanov², Petar Kolev³

¹Department of Synthetic Biology and Pharmaceutical Manufacturing, Faculty of Pharmacy, Sofia University, Sofia, Bulgaria.

²Department of Programmable Cell Factories, Faculty of Pharmacy, University of Plovdiv, Plovdiv, Bulgaria.

³Department of Bioprocess Design, Faculty of Pharmacy, University of Ruse, Ruse, Bulgaria.

*Email: elena.petrova@uni-sofia.bg

ABSTRACT

Pharmaceutical biomanufacturing has traditionally treated the production host, pathway configuration, process recipe, and quality-control system as partially separable optimization problems. Synthetic biology challenges that separation by making biological production systems increasingly specifiable, responsive, and iteratively redesignable. Yet programmability should not be equated with deterministic control. Genetic circuits remain context dependent, metabolic rewiring redistributes finite cellular resources, sensors have response and operating limits, engineered states can evolve, and apparently successful productivity interventions may alter product-quality attributes in ways that emerge only at process scale. This Perspective argues that the most consequential application of synthetic biology to pharmaceutical manufacturing is therefore not simply the construction of higher-producing cells. It is the gradual conversion of manufacturing into a design problem in which host state, pathway configuration, sensing, actuation, product quality, stability, and scale transfer are considered jointly. We propose a bounded architecture for this transition. Biological designs should progress through explicit validation gates separating circuit specification from intracellular performance, intracellular performance from process behavior, and process behavior from pharmaceutical quality. Programmable manufacturing would consequently mean an ability to design, observe, update, and requalify biological production states while preserving the distinction between a predicted state and a validated manufacturing state. Such a framework could make synthetic biology more relevant to pharmaceutical production without overstating the maturity, portability, or regulatory readiness of current systems.

Keywords: Synthetic biology, Biomanufacturing, Genetic circuits, Metabolic engineering, Process analytical technology, Critical quality attributes

Received: 1 October 2025; **Revised:** 18 December 2025; **Accepted:** 21 December 2025

INTRODUCTION

Synthetic biology has expanded the range of biological systems that can be designed rather than merely selected, but industrial biomanufacturing still depends on infrastructure, standardization, process transfer, and scale-aware implementation that are not solved by genetic engineering alone [1]. The resulting tension is especially important for pharmaceutical manufacturing. A strain or cell line can be genetically programmable while the overall production process remains operationally rigid, difficult to observe, or poorly transferable across scales. The manufacturing problem therefore begins where biological programmability meets process reality.

Modern synthetic-biology toolkits can alter genomes, sense intracellular or extracellular signals, and couple those signals to regulatory responses or metabolic flux [2]. These capabilities create a plausible route from static

biological production systems toward systems whose behavior can be specified, measured, and conditionally changed. However, the distinction between *programmable biology* and *programmable pharmaceutical manufacturing* must be preserved. The former can be demonstrated by a circuit or engineered pathway. The latter requires that the resulting state remain sufficiently observable, reproducible, stable, product-relevant, and controllable under manufacturing conditions.

This Perspective therefore proposes that pharmaceutical production should be treated increasingly as a constrained biological design-and-control problem. The proposed architecture does not assume that every manufacturing variable can be encoded genetically or that synthetic circuits can replace conventional process controls. Instead, it combines biological design with analytical observation, explicit scale-transfer boundaries, product-quality verification, and iterative redesign. The central question becomes not simply whether a host can be engineered to make more product, but whether the desired production state can be specified, reached, detected, maintained, and requalified without losing the pharmaceutical properties that matter.

From host selection to programmable production

Conventional cell-line development often begins with host selection followed by screening for productive clones. In mammalian biomanufacturing, however, targeted and semi-targeted transgene-integration technologies increasingly allow genomic location itself to become an explicit design variable rather than an uncontrolled consequence of random integration [3]. This shift is consequential because the genomic context of production constructs can affect expression stability and reproducibility. It does not make stability automatic, but it moves part of cell-line development from empirical selection toward specified construction.

Programmability also requires meaningful baselines. Reference CHO cell lines, media, and process platforms have been developed specifically to improve reproducibility and access to industrially relevant manufacturing research [4]. Such systems illustrate a broader principle: a programmable host cannot be interpreted independently of the process environment in which its behavior is measured. A genetic change evaluated in one cell background, medium, culture stage, or production regime may not retain the same functional meaning elsewhere.

This problem becomes sharper when production cultures change state over time. Fed-batch CHO processes traverse phases of growth, nutrient limitation, altered metabolism, stress, and productivity, motivating interest in synthetic systems that sense changing conditions and alter cellular behavior accordingly [5]. Dynamic engineering therefore differs conceptually from constitutive optimization. Rather than fixing a phenotype at cell-line creation, it seeks to make selected phenotypes conditional on production state.

The proposed transition from host selection to programmable production consequently has three layers. Host construction specifies an initial biological design; standardized process contexts make that design interpretable; and dynamic regulation permits selected functions to depend on the evolving manufacturing environment. None of these layers alone establishes a programmable pharmaceutical process. Their value lies in making biological state increasingly explicit and therefore increasingly testable.

Genetic circuits

Genetic circuits provide the logic layer through which biological states can be linked to designed responses. Their usefulness, however, depends on the quality and contextual characterization of the parts from which they are built. Available regulatory elements span transcriptional, translational, and post-translational mechanisms, but even apparently modular components can behave differently when host, copy number, promoter context, growth condition, or resource demand changes [6]. A manufacturing circuit should therefore be viewed less as an abstract wiring diagram than as a context-qualified biological implementation.

Design automation attempts to make this complexity manageable. Genetic design automation tools formalize circuit specifications, standards, part descriptions, and computational workflows so that biological designs can be assembled and evaluated before physical construction [7]. This abstraction is valuable because it separates the intended logical behavior from the particular DNA implementation. It is also potentially misleading if the abstraction boundary is treated as evidence that the underlying biology is equally standardized.

Cello 2.0 demonstrates how high-level functional specifications can be converted into DNA-level circuit designs using characterized gate libraries and formal design rules [8]. The important manufacturing lesson is not that biological circuits have become universally predictable. It is that a portion of the design problem can now be encoded computationally when the relevant parts and operating context have been sufficiently characterized. The design domain therefore has boundaries. Outside them, a formally correct circuit may still fail because the host,

burden, environment, or manufacturing state differs from the conditions under which its components were qualified.

For pharmaceutical production, genetic-circuit programmability should consequently be interpreted as a layered claim. The logical specification may be programmable, the DNA construction may be automatable, and the cellular response may be measurable, yet manufacturing suitability remains a separate state that must be demonstrated experimentally.

Metabolic pathway engineering

Metabolic engineering shifts programmability from information processing to material conversion. A production pathway competes with growth, maintenance, cofactor supply, precursor availability, and stress responses, so pathway design is not reducible to adding a sequence of biosynthetic enzymes. In engineered *Escherichia coli*, multilevel pathway modification combined with biosensor-assisted mutagenesis and screening has been used to search for high-producing L-arginine phenotypes, illustrating how rational redesign and phenotype-responsive exploration can operate together [9]. The example is product specific, but the design principle is broader: metabolic production can be treated as a searchable state space rather than a one-variable optimization.

The same logic becomes more complex for pharmaceutical-relevant natural products. Reconstitution of plant natural-product biosynthesis in microbial systems can require simultaneous engineering of pathway enzymes, precursor supply, chassis characteristics, subcellular organization, and sometimes multicellular or coculture arrangements [10]. In such systems, the “production program” is distributed across multiple biological layers. A nominally complete pathway therefore does not guarantee adequate flux, compatibility, stability, or manufacturability.

The proposed manufacturing interpretation is that metabolic pathway design should terminate not at pathway completion but at a validation boundary. Upstream of that boundary, genetic parts, pathway topology, host metabolism, and computational design define candidate production states. Downstream, those states must survive empirical tests of metabolic performance, resource compatibility, process dependence, and product relevance. This distinction prevents metabolic programmability from being mistaken for manufacturing determinism.

The pathway-level argument is more efficiently represented as a closed design field than as a linear sequence because pathway construction, host context, measurement, and redesign can recursively modify one another.




Figure 1. Metabolic design states require validation before they become manufacturing states

Dynamic control of biosynthesis

Static pathway engineering assumes that the preferred allocation of cellular resources is approximately constant. Dynamic control relaxes that assumption. A pyruvate-responsive regulatory circuit has been used to alter central metabolic allocation in response to intracellular state and improve production of two different microbial products relative to tested static configurations [11]. The importance of this result is conceptual as much as quantitative:

the engineered system responds to a metabolic variable rather than treating pathway activity as fixed throughout production.

Dynamic control can also be distributed across several regulatory layers. DNA-, RNA-, and protein-level tools provide different response speeds, implementation burdens, and control mechanisms, giving designers multiple routes for coupling an observed state to a biological action [12]. These options should not be treated as interchangeable. A transcriptional controller that is adequate for a slowly changing nutrient state may be poorly matched to a disturbance requiring rapid response, whereas faster regulation may impose different complexity or resource demands.

Actuation also has physical boundaries. Optogenetic regulation can provide externally addressable control of biosynthesis, including operation at bioreactor scale, but light delivery becomes more difficult as biomass density and optical path constraints increase [13]. A circuit may therefore retain its logical behavior while losing effective controllability because the actuator cannot be delivered uniformly to the manufacturing system.

For programmable pharmaceutical production, a control decision should consequently depend on four distinct questions: what production state is inferred, how reliable that inference is, which biological action is feasible at the required time scale, and what observation would justify revising that action. These questions motivate a decision-state ledger rather than a static comparison of control technologies.

The analytical value of such a ledger is that it prevents “dynamic control” from being treated as a single favorable state and instead exposes when intervention is justified, provisional, or physically constrained.

Table 1. Decision states for conditional control of biosynthetic production

Metabolic diversion is detectable before the production objective is lost Production demand and host demand are beginning to conflict A dynamic controller outperforms its static comparator under the tested operating state Actuator delivery becomes spatially or temporally limiting State evidence is insufficient to distinguish competing explanations					
Proposed control decision state	Metabolic diversion is detectable before the production objective is lost	Production demand and host demand are beginning to conflict	A dynamic controller outperforms its static comparator under the tested operating state	Actuator delivery becomes spatially or temporally limiting	State evidence is insufficient to distinguish competing explanations
Information available at that state	A state-linked metabolic signal changes in a direction associated with altered pathway allocation	Growth or metabolic behavior indicates that constitutive pathway pressure is no longer neutral to the host	Controlled production improves while the tested biological state remains acceptable	Circuit logic remains functional but the physical control input becomes heterogeneous	Available observations are compatible with more than one metabolic or process state
Unresolved uncertainty	Whether the signal is sufficiently specific to the targeted flux change	Whether resource limitation or another process disturbance is the dominant cause	Whether the advantage persists across later culture phases, products, or scales	Whether observed nonuniformity originates from biology or actuator transport	Which hidden state actually requires intervention
Permissible control response	Apply a previously qualified state-responsive adjustment rather than globally increasing expression	Reduce, delay, or redistribute biosynthetic demand if the relevant controller has been qualified	Retain conditional control only within the demonstrated operating domain	Restrict intervention to the range in which the actuator can be delivered reproducibly	Withhold irreversible control changes and obtain additional discriminating information

Observation requiring reassessment	Productive flux fails to recover or a second state indicator moves adversely	Host performance continues to deteriorate despite reduced pathway pressure	The operating state moves outside the conditions used to characterize the controller	Increased biomass, geometry, mixing, or scale changes actuator exposure	A new observation resolves the competing state interpretations
---	--	--	--	---	--

Note. The decision-state labels and permissible-response logic are proposed synthesis derived from the manuscript. They are not universal operating rules, numerical thresholds, or validated release criteria.

Sensor–actuator manufacturing systems

A programmable process requires more than a sensor that changes output. The sensor must produce information with sufficient specificity, response time, dynamic range, stability, and reproducibility to support the intended decision. Smart biosensing approaches are increasingly positioned as interfaces between intracellular state and external or genetically encoded feedback, but noise, response characteristics, calibration, and scale robustness remain important constraints [14]. Sensing should therefore be separated conceptually from actionability.

External process analytical technology provides a complementary observation layer. Automated sampling and analytical platforms can shorten the delay between process state and measured attributes, supporting more timely process understanding and potentially faster control decisions [15]. Such systems are particularly relevant when the biologically informative variable cannot be measured reliably by an intracellular circuit or when direct analytical confirmation of a product or process attribute is preferable.

Even intracellular sensor properties are themselves design variables. Engineering of a p-coumaric-acid biosensor demonstrated that regulator and promoter modifications can change sensitivity, strength, and dynamic range [16]. The implication is that the boundary between “sensor present” and “sensor absent” is analytically inadequate. A manufacturing sensor must be characterized within the range, host, time scale, and process environment in which its signal will be interpreted.

The proposed sensor–actuator architecture therefore contains two observation routes. Biological sensors can expose intracellular states that conventional analytics may not see directly, while external PAT can measure process or product states with analytically established methods. Neither route should automatically dominate. Their value depends on whether the measured variable is causally or predictively relevant to the intended intervention and whether the resulting action remains reversible, observable, and qualified.

Product quality by biological design

The strongest limitation of yield-centered synthetic biology is that pharmaceutical products are defined by more than quantity. Process variables can propagate through cellular metabolism into product attributes. In CHO production, culture pH has been linked experimentally to changes in metabolism, antibody production, and site-specific N-linked glycosylation, demonstrating that a manufacturing perturbation can simultaneously alter cellular state and a quality-relevant product feature [17]. Product quality must therefore remain an explicit output of any programmable manufacturing architecture.

Genome-scale models may help expose the hidden metabolic state connecting process conditions to observed outputs. CHO genome-scale metabolic models are increasingly used to organize mechanistic process information and are being discussed as components of more digital biomanufacturing strategies [18]. Their usefulness is substantial but bounded: a model-generated state estimate is not equivalent to a validated measurement, and the proposed integration of metabolic models with more autonomous control remains dependent on model scope, training data, process context, and independent verification.

Host engineering similarly illustrates why productivity and quality should not be collapsed. CRISPR-Cas9 engineering of CHO-K1 cells has altered production-related phenotypes and improved heterologous-protein output in specific experimental systems [19]. Such results establish that genomic engineering can modify the productive capacity of a host. They do not establish that every productivity gain preserves glycosylation, folding, charge variants, aggregation behavior, or other product-specific quality attributes.

We therefore propose that product quality be incorporated into the biological design objective rather than inspected only after the production design has been optimized. This does not mean that every critical quality attribute can be programmed directly. It means that synthetic-biology interventions should be judged by how they alter the coupled host–process–product state, with direct analytical evidence retained as the boundary between inferred quality and demonstrated quality.

That distinction is best represented as a sensor–actuator network in which biological state estimates, external measurements, engineered responses, and product-quality evidence remain connected but analytically non-equivalent.




Figure 2. Product-quality control requires separation of sensed state, inferred state, biological action, and demonstrated attribute

Evolutionary instability and burden

Programmability imposes costs on the host that carries it. Recombinant expression, pathway redirection, and environmental perturbation can redistribute finite cellular resources and compromise robustness when production demand becomes excessive [20]. Genome-scale metabolism-and-expression models further show that recombinant-expression burden can, within defined systems, be related to design variables such as promoter strength and copy number, making burden a potentially modelable constraint rather than merely a post hoc failure [21].

A second limitation is evolutionary persistence. Engineered *Escherichia coli* Nissle populations exposed to scale-up simulation accumulated genetic heterogeneity, with production cassettes becoming mutation targets during extended propagation [22]. Feedback can mitigate some host–circuit conflicts: autonegative regulation has reduced transcription-factor-associated burden and restored circuit function in tested bacterial systems [23]. Such mitigation should not be confused with eliminating resource competition or evolutionary selection. A programmable manufacturing state must therefore be evaluated not only for whether it can be reached, but also for whether it persists long enough to remain pharmaceutically meaningful.

Table 2. Cross-scale propagation routes by which engineered-state instability can acquire manufacturing significance

Propagation scenario	Context	Observation	Interpretation	Boundary	Decision
Scientific anchor	Disturbance source Process Hidden biological state	Measured variable	Propagation path	Transferability boundary	Manufacturing consequence

Expression demand progressively exceeds host capacity	Disturbance source Strong synthetic-program demand Process or cellular state Resource-limited production state Hidden biological state requiring interpretation Allocation of translational and metabolic resources	Growth, productivity, metabolic indicators	Circuit demand → host burden → altered production phenotype	Host, construct and process dependent	Controller or expression design requires reassessment
A production construct loses population uniformity	Disturbance source Mutation or selection during propagation Process or cellular state Genetically heterogeneous culture Hidden biological state requiring interpretation Relative fitness of emerging variants	Sequence or population-state evidence	Engineered cassette → variant expansion → production drift	Evolutionary trajectory is platform specific	Genetic stability becomes a process-state variable
Process conditions reshape product-relevant metabolism	Disturbance source Environmental or operating perturbation Process or cellular state Altered cellular metabolic state Hidden biological state requiring interpretation Intracellular flux and processing state	Process and product measurements	Process disturbance → cellular response → product attribute	Product and process specific	Direct CQA verification remains necessary
Burden-control feedback restores function only within a qualified domain	Disturbance source Excess regulator or pathway demand Process or cellular state Feedback-modulated state Hidden biological state requiring interpretation Residual resource conflict	Circuit output and host-performance indicators	Sensing → corrective regulation → revised host demand	Circuit architecture and operating range	Mitigation must be revalidated after material process change

Note. The propagation categories and manufacturing interpretations are proposed synthesis. They do not constitute universal causal chains, regulatory decision rules, or validated quantitative thresholds.

Design–build–test–learn for pharmaceutical production

Design–build–test–learn converts engineering from one-pass optimization into iterative evidence accumulation. Simulated DBTL studies show that machine-learning performance depends on data availability, noise, algorithm choice, and how experiments are allocated across cycles [24]. Automated platforms have also demonstrated physical closure of the loop between computational recommendation, robotic experimentation, measurement, and redesign in a microbial production system [25].

For pharmaceutical manufacturing, the proposed extension is broader than optimizing titer. Future DBTL cycles should treat product quality, host burden, genetic stability, sensor reliability, actuator feasibility, and scale transfer as coexisting design constraints. A candidate should advance because its manufacturing state becomes better supported, not merely because one output improves.

Scale-up and regulatory challenges

Scale-up tests whether biological programmability survives changes in geometry, transport, population structure, and observation quality. Optogenetic control illustrates how an actuator can become physically constrained at high biomass despite functional circuit logic [13], while engineered-population studies show that prolonged scale-relevant propagation can alter genetic composition [22]. These are different failure mechanisms, but both demonstrate why laboratory control cannot be assumed to remain invariant after scale transfer.

Greater observability can narrow this gap. Automated PAT can shorten analytical latency [15], and direct product-quality measurements can reveal consequences that productivity alone misses [17]. Genome-scale models may

further support state estimation, but model output remains an inference requiring domain-specific validation [18]. Consequently, a regulatory case for programmable manufacturing would need traceable design states, qualified measurements, controlled change, stability evidence, and product-specific validation rather than a generic assertion of synthetic-biology sophistication. Enabling infrastructure and harmonized workflows may support that transition [1], while design standards [7] and iterative-learning methods [24] can improve traceability. Automated DBTL nevertheless remains evidence of technical feasibility rather than proof of autonomous pharmaceutical manufacturing [25].

CONCLUSION

Synthetic biology can make pharmaceutical manufacturing more programmable, but programmability should be defined as the capacity to specify, observe, control, test, and revise biological production states under explicit validation boundaries. The proposed architecture therefore links host and pathway design with sensing, actuation, product-quality evidence, stability, and iterative learning while refusing to equate model prediction with measurement, productivity with quality, or laboratory control with scale-ready manufacturing. The opportunity is not a factory that biology makes deterministic, but a manufacturing system in which biological uncertainty becomes increasingly designable, observable, and experimentally governable.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Asin-Garcia E, Fawcett JD, Batianis C, Martins Dos Santos VAP. A snapshot of biomanufacturing and the need for enabling research infrastructure. *Trends Biotechnol.* 2025;43(5):1000-14. doi:10.1016/j.tibtech.2024.10.014
2. Han YH, Kim G, Seo SW. Programmable synthetic biology tools for developing microbial cell factories. *Curr Opin Biotechnol.* 2023;79:102874. doi:10.1016/j.copbio.2022.102874
3. Zeh N, Schmidt M, Schulz P, Fischer S. The new frontier in CHO cell line development: From random to targeted transgene integration technologies. *Biotechnol Adv.* 2024;75:108402. doi:10.1016/j.biotechadv.2024.108402
4. Cordova LT, Dahodwala H, Elliott KS, Baik J, Odenewelder DC, Nmagu D, et al. Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturing. *Biotechnol Bioeng.* 2023;120(3):715-25. doi:10.1002/bit.28290
5. Donaldson J, Kleinjan DJ, Rosser S. Synthetic biology approaches for dynamic CHO cell engineering. *Curr Opin Biotechnol.* 2022;78:102806. doi:10.1016/j.copbio.2022.102806
6. Buson F, Gao Y, Wang B. Genetic parts and enabling tools for biocircuit design. *ACS Synth Biol.* 2024;13(3):697-713. doi:10.1021/acssynbio.3c00691
7. Buecherl L, Myers CJ. Engineering genetic circuits: Advancements in genetic design automation tools and standards for synthetic biology. *Curr Opin Microbiol.* 2022;68:102155. doi:10.1016/j.mib.2022.102155
8. Jones TS, Oliveira SMD, Myers CJ, Voigt CA, Densmore D. Genetic circuit design automation with Cello 2.0. *Nat Protoc.* 2022;17(4):1097-113. doi:10.1038/s41596-021-00675-2
9. Jiang S, Wang R, Wang D, Zhao C, Ma Q, Wu H, et al. Metabolic reprogramming and biosensor-assisted mutagenesis screening for high-level production of L-arginine in *Escherichia coli*. *Metab Eng.* 2023;76:146-57. doi:10.1016/j.ymben.2023.02.003
10. Gao J, Gou Y, Huang L, Lian J. Reconstitution and optimization of complex plant natural product biosynthetic pathways in microbial expression systems. *Curr Opin Biotechnol.* 2024;87:103136. doi:10.1016/j.copbio.2024.103136
11. Zou Y, Gong X, Zhang J, Gan Q, Yan Y. Engineering genetic circuits for dynamic control of central metabolism. *Metab Eng.* 2025;91:405-14. doi:10.1016/j.ymben.2025.06.007

12. Qin H, Zhou J, Pang A, Huang L, Liu Z, Zheng Y. Microbial dynamic regulatory tools: Design, applications, and prospects. *ACS Synth Biol.* 2025;14(7):2418-32. doi:10.1021/acssynbio.5c00219
13. Zhao EM, Lalwani MA, Chen JM, Orillac P, Toettcher JE, Avalos JL. Optogenetic amplification circuits for light-induced metabolic control. *ACS Synth Biol.* 2021;10(5):1143-54. doi:10.1021/acssynbio.0c00642
14. Pisani M, Carbonell P. Challenges and opportunities in smart biosensing for biomanufacturing. *ACS Synth Biol.* 2025;14(9):3267-74. doi:10.1021/acssynbio.5c00203
15. Wu CHR, Chan B, Sarich Z, Duan Y, Chen J, Song JL, et al. Accelerating attribute-focused process and product development through the development and deployment of autonomous process analytical technology platform system. *Biotechnol Bioeng.* 2024;121(4):1257-70. doi:10.1002/bit.28649
16. Jiang T, Li C, Yan Y. Optimization of a p-coumaric acid biosensor system for versatile dynamic performance. *ACS Synth Biol.* 2021;10(1):132-44. doi:10.1021/acssynbio.0c00500
17. Venkatarama Reddy J, Singh SK, Leibiger T, Lee KH, Ierapetritou M, Papoutsakis ET. Flux balance analysis and peptide mapping elucidate the impact of bioreactor pH on Chinese hamster ovary (CHO) cell metabolism and N-linked glycosylation in the fab and Fc regions of the produced IgG. *Metab Eng.* 2025;87:37-48. doi:10.1016/j.ymben.2024.11.005
18. Park SY, Choi DH, Song J, Lakshmanan M, Richelle A, Yoon S, et al. Driving towards digital biomanufacturing by CHO genome-scale models. *Trends Biotechnol.* 2024;42(9):1192-203. doi:10.1016/j.tibtech.2024.03.001
19. Wang W, Zheng W, Hu F, He X, Wu D, Zhang W, et al. Enhanced biosynthesis performance of heterologous proteins in CHO-K1 cells using CRISPR-Cas9. *ACS Synth Biol.* 2018;7(5):1259-68. doi:10.1021/acssynbio.7b00375
20. Mao J, Zhang H, Chen Y, Wei L, Liu J, Nielsen J, et al. Relieving metabolic burden to improve robustness and bioproduction by industrial microorganisms. *Biotechnol Adv.* 2024;74:108401. doi:10.1016/j.biotechadv.2024.108401
21. Oftadeh O, Hatzimanikatis V. Genome-scale models of metabolism and expression predict the metabolic burden of recombinant protein expression. *Metab Eng.* 2024;84:109-16. doi:10.1016/j.ymben.2024.06.005
22. Munkler LP, Mohamed ET, Vazquez-Urbe R, Nissen VV, Rugbjerg P, Worberg A, et al. Genetic heterogeneity of engineered *Escherichia coli* Nissle 1917 strains during scale-up simulation. *Metab Eng.* 2024;85:159-66. doi:10.1016/j.ymben.2024.08.001
23. Guan Y, Chen X, Shao B, Ji X, Xiang Y, Jiang G, et al. Mitigating host burden of genetic circuits by engineering autonegatively regulated parts and improving functional prediction. *ACS Synth Biol.* 2022;11(7):2361-71. doi:10.1021/acssynbio.2c00073
24. van Lent P, Schmitz J, Abeel T. Simulated design-build-test-learn cycles for consistent comparison of machine learning methods in metabolic engineering. *ACS Synth Biol.* 2023;12(9):2588-99. doi:10.1021/acssynbio.3c00186
25. Hamedirad M, Chao R, Weisberg S, Lian J, Sinha S, Zhao H. Towards a fully automated algorithm driven platform for biosystems design. *Nat Commun.* 2019;10(1):5150. doi:10.1038/s41467-019-13189-z